{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-AIP3C2WP/836a73fd-1d8e-40c3-8085-88ac8981b503/PDF","dcterms:extent":"430 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-AIP3C2WP/afb01d61-91fd-48b6-8958-6d82dd3db2ab/TEXT","dcterms:extent":"14 KB"}],"edm:TimeSpan":{"@rdf:about":"1997-2025","edm:begin":{"@xml:lang":"en","#text":"1997"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-AIP3C2WP","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-S2P9OQWZ"},{"@xml:lang":"sl","#text":"Onkologija (Ljubljana)"}],"dcterms:issued":"2016","dc:creator":"Grašič-Kuhar, Cvetka","dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:20"},{"@xml:lang":"sl","#text":"str. 4-6"}],"dc:identifier":["ISSN:1408-1741","COBISSID_HOST:2415739","URN:URN:NBN:SI:doc-AIP3C2WP"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"dc:subject":[{"@xml:lang":"sl","#text":"karcinom"},{"@xml:lang":"en","#text":"medullary thyroid carcinoma"},{"@xml:lang":"sl","#text":"napredovali rak"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"sl","#text":"sistemsko zdravljenje"},{"@xml:lang":"en","#text":"systemic treatment"},{"@xml:lang":"sl","#text":"ščitnica"},{"@xml:lang":"en","#text":"thyroid cancer"}],"dcterms:temporal":{"@rdf:resource":"1997-2025"},"dc:title":{"@xml:lang":"sl","#text":"Sistemsko zdravljenje napredovalega medularnega karcinoma ščitnice|"},"dc:description":{"@xml:lang":"sl","#text":"Medularni karcinom ščitnice nastane iz nevroendokrinih celic ščitnice, ki izločajo kalcitonin. Kalcitonin je specifičen marker medularnega raka ščitnice. Pri lokalno napredovalem ali metastaskem medularnem raku ščitnice ob simptomtskem progresu prihaja v poštev zdravljenje s tirozin kinaznimi inhibitorji. Registrirani substanci sta vandetanib in cabozantinib, učinkoviti pa sta tudi sorafenib in sunitinib. Izbira zdravljenja je individualizirana glede na breme bolezni in spremljajoče bolezni. Zelo pomembno je tudi podporno (na simptome usmerjeno) zdravljenje"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-AIP3C2WP","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-AIP3C2WP"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-AIP3C2WP/836a73fd-1d8e-40c3-8085-88ac8981b503/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-AIP3C2WP/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-AIP3C2WP"}}}}